Empagliflozin for cardiomyopathy, hypertrophic

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 1 Aug 2022: Trial started, NCT06401343
  2. 6 May 2024: Trial registered, NCT06401343

The trials

NCT06401343: Use of SGLT2i in noHCM With HFpEF

State
State not given
Phase
Phase 4
People
94 planned
Started
1 Aug 2022
Primary completion
1 Aug 2024
Arms
Study group
Results
None posted
  1. 1 Aug 2022: Trial started
  2. 6 May 2024: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Also known as Empagliflozin 10 MG, Empagliflozin 10 MG OD, Empagliflozin 25 MG, Empagliflozin10Mg Tab, Glyxambi component empagliflozin, Jardiance, Trijardy xr component empagliflozin.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.